Dr. Ali El-Ghamrawy:
We Are Keen to Strengthen Arab Cooperation and Exchange Expertise to Support the Development of Pharmaceutical Regulatory Systems
Dr. Ali El-Ghamrawy:
We Are Working to Build Effective Regulatory Systems that Ensure the Quality, Safety, and Efficacy of Medical Products and Enhance Pharmaceutical Security Regionally and Internationally
Lebanese Minister of Public Health:
We Commend the Egyptian Drug Authority’s Role in Advancing Pharmaceutical Regulatory Systems and Strengthening Quality and Safety Standards
Lebanese Minister of Public Health:
It Is Essential to Benefit from Successful Regional Experiences in Developing a Modern Pharmaceutical System Based on Efficiency, Governance, and Regulatory Excellence

Dr. Ali El-Ghamrawy, Chairman of the Egyptian Drug Authority (EDA), held a meeting with Dr. Rakan Nassereldine, Minister of Public Health of the Republic of Lebanon, to discuss avenues for strengthening cooperation in pharmaceutical and regulatory affairs and exchanging expertise to support the development of regulatory systems and enhance pharmaceutical security.

During the meeting, Dr. El-Ghamrawy emphasized the Egyptian Drug Authority’s commitment to strengthening Arab cooperation in pharmaceutical regulation and regulatory system development. He noted that Egypt’s experience has become a leading regional model in areas including product registration, inspection, pharmacovigilance, digital transformation, and capacity building.

He further highlighted the EDA’s continued commitment to knowledge transfer and the exchange of expertise, contributing to the establishment of effective regulatory systems that ensure the quality, safety, and efficacy of medical products while promoting pharmaceutical security at both the regional and international levels.

Dr. El-Ghamrawy also reviewed Egypt’s pioneering experience in advancing its pharmaceutical regulatory framework and highlighted the Authority’s achievements in institutional development and capacity building in line with the latest international standards and best practices.

For his part, Dr. Rakan Nassereldine expressed his appreciation for Egypt’s advanced experience in pharmaceutical regulation and reaffirmed Lebanon’s interest in strengthening cooperation with the Egyptian Drug Authority and benefiting from its expertise in developing the national regulatory system.

He also highlighted the Lebanese Ministry of Public Health’s efforts to establish a more integrated institutional framework for pharmaceuticals and emphasized the importance of continued coordination and partnership with the Egyptian side to support capacity building and regulatory development, ultimately enhancing the quality of healthcare and pharmaceutical services in Lebanon.

The two sides explored opportunities for technical and institutional cooperation through the exchange of expertise and best practices in pharmaceutical oversight and regulatory development, as well as support for capacity-building programs and the training of technical personnel. These efforts aim to enhance the efficiency of regulatory systems and improve the quality of services provided to the pharmaceutical sector.

Discussions further addressed opportunities for cooperation in facilitating access to medical products, exchanging regulatory information and expertise, and strengthening integration among health and pharmaceutical institutions in both countries, thereby contributing to ensuring the quality, safety, and efficacy of medical products.

Both parties reaffirmed the importance of maintaining coordination and communication during the coming period and working toward practical mechanisms for cooperation that serve mutual interests and support ongoing efforts to advance pharmaceutical and healthcare systems.

The meeting comes within the framework of the Egyptian Drug Authority’s commitment to strengthening cooperation with sister Arab countries and promoting the exchange of expertise and regulatory best practices. These efforts reinforce the Authority’s position as a leading regional center for pharmaceutical regulation and support the achievement of pharmaceutical security in accordance with the latest international standards.